Skip to main content

Kidney Cancer


Pembrolizumab plus axitinib is associated with greater QALYs compared with nivolumab plus ipilimumab for patients with advanced RCC, but may not be cost-effective.
Conference Coverage
Nivolumab in combination with ipilimumab is a potential cost-effective treatment option for patients with intermediate…
Percutaneous cryoablation may be as effective as surgery for treating stage I renal cell carcinoma, according to the…
The risk of recurrence in surgically treated renal-cell carcinoma persists beyond 5 years after surgery, suggesting the…
Toni Choueiri, MD, discusses surgical considerations and multidisciplinary care for localized kidney cancer, adjuvant…
Back to Top